{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:17:34Z","timestamp":1790738254830,"version":"4.1.0"},"reference-count":155,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.008","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:42Z","timestamp":1749770142000},"page":"304-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Health Disparities and Inequities in Prostate Cancer Along the Continuum of Care"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4378-117X","authenticated-orcid":false,"given":"Ulysses","family":"Gardner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison B.","family":"Randolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Anabaraonye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Washington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Curtiland","family":"Deville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J Clin"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0002","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of prostate cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0004","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: Findings from the prospective lynch syndrome database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"issue":"16","key":"10.1016\/j.semradonc.2025.04.008_bib0005","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1200\/JCO.19.02808","article-title":"Risk of prostate cancer associated with familial and hereditary cancer syndromes","volume":"38","author":"Beebe-Dimmer","year":"2020","journal-title":"JCO"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.008_bib0006","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwx235","article-title":"TMPRSS2:ERG gene fusions in prostate cancer of West African men and a meta-analysis of racial differences","volume":"186","author":"Zhou","year":"2017","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0007","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/s41467-022-29235-2","article-title":"Serum proteomics links suppression of tumor immunity to ancestry and lethal prostate cancer","volume":"13","author":"Minas","year":"2022","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.33546","article-title":"West African genetic ancestry, neighborhood deprivation, and prostate cancer","volume":"7","author":"Pichardo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.770500","article-title":"Genetic contributions to prostate cancer disparities in men of West African descent","volume":"11","author":"Johnson","year":"2021","journal-title":"Front Oncol"},{"issue":"38","key":"10.1016\/j.semradonc.2025.04.008_bib0010","doi-asserted-by":"crossref","first-page":"14068","DOI":"10.1073\/pnas.0605832103","article-title":"Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men","volume":"103","author":"Freedman","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s42003-021-01681-6","article-title":"Genetic ancestry plays a central role in population pharmacogenomics","volume":"4","author":"Yang","year":"2021","journal-title":"Commun Biol"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0012","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3389\/fonc.2018.00500","article-title":"The influence of metabolism on drug response in cancer","volume":"8","author":"Zaal","year":"2018","journal-title":"Front Oncol"},{"issue":"5507","key":"10.1016\/j.semradonc.2025.04.008_bib0013","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1126\/science.1058040","article-title":"The sequence of the human genome","volume":"291","author":"Venter","year":"2001","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.008_bib0014","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1101\/gr.4413105","article-title":"The International HapMap Project web site: figure 1","volume":"15","author":"Thorisson","year":"2005","journal-title":"Genome Res"},{"issue":"7571","key":"10.1016\/j.semradonc.2025.04.008_bib0015","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A global reference for human genetic variation","volume":"526","year":"2015","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0016","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaoncol.2016.1854","article-title":"Racial\/ethnic disparities in genomic sequencing","volume":"2","author":"Spratt","year":"2016","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0017","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41698-023-00351-6","article-title":"Racial and ethnic disparities in a real-world precision oncology data registry","volume":"7","author":"Cheung","year":"2023","journal-title":"NPJ Precis Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.008_bib0018","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1158\/1055-9965.EPI-19-1616","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0019","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jamaoncol.2022.5511","article-title":"Disparities in the inclusion of racial and Ethnic Minority groups and older adults in prostate cancer clinical trials: A meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0020","unstructured":"National Institutes of Health. Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research. National Institutes of Health. Accessed January 6, 2025. https:\/\/grants.nih.gov\/grants\/funding\/women_min\/guidelines.htm."},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.008_bib0021","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.2105\/AJPH.2005.068668","article-title":"Latino populations: A unique opportunity for the study of race, genetics, and social environment in epidemiological research","volume":"95","author":"Gonz\u00e1lez Burchard","year":"2005","journal-title":"Am J Public Health"},{"issue":"5748","key":"10.1016\/j.semradonc.2025.04.008_bib0022","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.008_bib0023","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0024","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2009.04.036","article-title":"ETS gene fusions in prostate cancer: From discovery to daily clinical practice","volume":"56","author":"Tomlins","year":"2009","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0025","doi-asserted-by":"crossref","first-page":"982","DOI":"10.3892\/mco.2014.378","article-title":"Predominance of ERG-negative high-grade prostate cancers in African American men","volume":"2","author":"Farrell","year":"2014","journal-title":"Mol Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0026","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.urology.2012.07.001","article-title":"Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer","volume":"80","author":"Rosen","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0027","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1200\/PO.21.00340","article-title":"Tumor mutations across racial groups in a real-world data registry","volume":"5","author":"Kamran","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0028","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3892\/mco.2014.418","article-title":"ERG oncoprotein expression in prostate carcinoma patients of different ethnicities","volume":"3","author":"Kelly","year":"2015","journal-title":"Mol Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0029","unstructured":"National Comprehensive Cancer. NCCN Guidelines: Genetic\/Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. National Comprehensive Cancer Network. Accessed January 6, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1544"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0030","unstructured":"National Comprehensive Cancer. NCCN Guidelines: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, Prostate, vs. 2 2025. National Comprehensive Cancer Network. Accessed January 6, 2025. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1545"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0031","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0032","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41585-022-00622-0","article-title":"Race and prostate cancer: genomic landscape","volume":"19","author":"Arenas-Gallo","year":"2022","journal-title":"Nat Rev Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0033","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.eururo.2016.07.026","article-title":"Prevalence and prognostic significance of PTEN loss in African-American and European-American men undergoing radical prostatectomy","volume":"71","author":"Tosoian","year":"2017","journal-title":"Eur Urol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.008_bib0034","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0035","article-title":"TP53 Mutations in Human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harbor Persp Biol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/2159-8290.CD-13-0136","article-title":"Contribution of p53 to Metastasis","volume":"4","author":"Powell","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0037","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/jnci\/89.2.158","article-title":"p53 Status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610","volume":"89","author":"Grignon","year":"1997","journal-title":"JNCI J Natl Cancer Institute"},{"issue":"17","key":"10.1016\/j.semradonc.2025.04.008_bib0038","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1158\/1078-0432.CCR-19-4112","article-title":"Genomic profiling of prostate cancers from men with African and European ancestry","volume":"26","author":"Koga","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0039","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cca.2014.02.014","article-title":"TATI as a biomarker","volume":"431","author":"Itkonen","year":"2014","journal-title":"Clinica Chimica Acta"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0040","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1373\/clinchem.2015.241513","article-title":"Emerging roles of SPINK1 in cancer","volume":"62","author":"R\u00e4s\u00e4nen","year":"2016","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0041","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pros.23705","article-title":"Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men","volume":"79","author":"Koide","year":"2019","journal-title":"The Prostate"},{"issue":"18","key":"10.1016\/j.semradonc.2025.04.008_bib0042","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1158\/1078-0432.CCR-13-2265","article-title":"Evidence for molecular differences in prostate cancer between African American and Caucasian men","volume":"20","author":"Khani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0043","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00020","article-title":"FOXA1 mutations in hormone-dependent cancers","volume":"3","author":"Robinson","year":"2013","journal-title":"Front Oncol"},{"issue":"7801","key":"10.1016\/j.semradonc.2025.04.008_bib0044","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41586-020-2135-x","article-title":"A genomic and epigenomic atlas of prostate cancer in Asian populations","volume":"580","author":"Li","year":"2020","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0045","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.gendis.2019.10.018","article-title":"Epigenetic regulation of prostate cancer","volume":"7","author":"Wang","year":"2020","journal-title":"Genes & Diseases"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0046","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nm.4341","article-title":"Biology and evolution of poorly differentiated neuroendocrine tumors","volume":"23","author":"Rickman","year":"2017","journal-title":"Nat Med"},{"issue":"14","key":"10.1016\/j.semradonc.2025.04.008_bib0047","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-09-3342","article-title":"Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men","volume":"16","author":"Kwabi-Addo","year":"2010","journal-title":"Clinical Cancer Research"},{"issue":"15_suppl","key":"10.1016\/j.semradonc.2025.04.008_bib0048","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.5003","article-title":"Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis","volume":"39","author":"Sivakumar","year":"2021","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0049","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jncc.2022.12.001","article-title":"A global perspective on the ethnic-specific BRCA variation and its implication in clinical application","volume":"3","author":"Wang","year":"2023","journal-title":"J Natl Cancer Center"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066855","article-title":"Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. Creighton C, ed","volume":"8","author":"Erho","year":"2013","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0051","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/s41391-019-0197-3","article-title":"Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting","volume":"23","author":"Howard","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.008_bib0052","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djac162","article-title":"Genomic testing in localized prostate cancer can identify subsets of African Americans with aggressive disease","volume":"114","author":"Awasthi","year":"2022","journal-title":"JNCI: J Natl Cancer Institute"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0053","doi-asserted-by":"crossref","first-page":"254.e15","DOI":"10.1016\/j.urolonc.2015.12.018","article-title":"The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men","volume":"34","author":"Kongnyuy","year":"2016","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0054","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.eururo.2015.09.031","article-title":"Racial variations in prostate cancer molecular subtypes and androgen receptor signaling reflect anatomic tumor location","volume":"70","author":"Faisal","year":"2016","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0055","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/j.juro.2010.01.015","article-title":"Evidence supports a faster growth rate and\/or earlier transformation to clinically significant prostate cancer in Black than in White American men, and influences racial progression and mortality disparity","volume":"183","author":"Powell","year":"2010","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0056","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/pros.21314","article-title":"Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer","volume":"71","author":"Chornokur","year":"2011","journal-title":"The Prostate"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0057","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10552-023-01807-7","article-title":"Prostate-specific antigen testing rates in high-risk populations: results from the All of Us Research Program","volume":"35","author":"Morley","year":"2024","journal-title":"Cancer Causes Cntrl"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0058","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241275389","article-title":"Understanding and addressing prostate cancer disparities in diagnosis, treatment, and outcomes among Black men","volume":"31","author":"Murphy","year":"2024","journal-title":"Cancer Control"},{"issue":"21","key":"10.1016\/j.semradonc.2025.04.008_bib0059","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1002\/cncr.34433","article-title":"Racial disparities in B lack men with prostate cancer: A literature review","volume":"128","author":"Lillard","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0060","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3122\/jabfm.2021.05.210149","article-title":"Barriers and facilitators to informed decision-making about prostate cancer screening among Black men","volume":"34","author":"Shungu","year":"2021","journal-title":"J Am Board Fam Med"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0061","first-page":"492","article-title":"Social ecological predictors of prostate-specific antigen blood test and digital rectal examination in Black American men","volume":"98","author":"Woods","year":"2006","journal-title":"J Natl Med Assoc"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0062","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/pcan.2017.32","article-title":"The impact of sociodemographic factors and PSA screening among low-income Black and White men: Data from the Southern Community Cohort Study","volume":"20","author":"Moses","year":"2017","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0063","article-title":"Prostate cancer screening and diagnoses in the transfeminine population","author":"Stephens","year":"2024","journal-title":"Urology"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0064","unstructured":"U.S. Preventative Services Task Force, Screening for Prostate Cancer, 2012, U.S. Preventative Services Task Force. Accessed March 1, 2025. https:\/\/www.bing.com\/ck\/a?!&&p=107b057de6751fa41591c70cf0e0beb1d0de7181ac26c6c4f3a37ea8aed25215JmltdHM9MTc0MTM5MjAwMA&ptn=3&ver=2&hsh=4&fclid=060e1e6f-782c-615e-3afc-0f99799b60ac&psq=uspstf+prostate+cancer+screenings+2012&u=a1aHR0cHM6Ly93d3cudXNwcmV2ZW50aXZlc2VydmljZXN0YXNrZm9yY2Uub3JnL2hvbWUvZ2V0ZmlsZWJ5dG9rZW4vdkN6UFZyVkpmZ0ZXZnBXUmRFSE1LUQ&ntb=1."},{"issue":"22","key":"10.1016\/j.semradonc.2025.04.008_bib0065","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2015.61.6532","article-title":"National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening","volume":"33","author":"Drazer","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0066","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11869","article-title":"Association of the USPSTF grade D recommendation against prostate-specific antigen screening with prostate cancer-specific mortality","volume":"5","author":"Burgess","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.semradonc.2025.04.008_bib0067","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer: US Preventive Services Task Force recommendation statement","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0068","unstructured":"American Urological Association. Prostate Cancer Guidelines. American Urological Association. Accessed March 1, 2025. https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/oncology-guidelines\/prostate-cancer"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.008_bib0069","doi-asserted-by":"crossref","first-page":"460.e9","DOI":"10.1016\/j.urolonc.2017.01.023","article-title":"Racial differences in prostate-specific antigen-based prostate cancer screening: State-by-state and region-by-region analyses","volume":"35","author":"Jindal","year":"2017","journal-title":"Urol Oncol"},{"issue":"629","key":"10.1016\/j.semradonc.2025.04.008_bib0070","doi-asserted-by":"crossref","first-page":"e783","DOI":"10.3399\/bjgp14X682861","article-title":"Digital rectal examination in primary care is important for early detection of prostate cancer: A retrospective cohort analysis study","volume":"64","author":"Walsh","year":"2014","journal-title":"Br J Gen Pract"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0071","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.juro.2017.10.021","article-title":"Use of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer","volume":"199","author":"Halpern","year":"2018","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0072","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.urology.2010.11.056","article-title":"Barriers and facilitators to digital rectal examination screening among African-American and African-Caribbean men","volume":"77","author":"Lee","year":"2011","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0073","first-page":"404","article-title":"Healthcare practices among Blacks and Whites with urinary tract symptoms","volume":"99","author":"Howard","year":"2007","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0074","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.urology.2014.03.012","article-title":"The impact of multiparametric pelvic magnetic resonance imaging on risk stratification in patients with localized prostate cancer","volume":"84","author":"Marcus","year":"2014","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/0284185114561915","article-title":"The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer","volume":"57","author":"Nowak","year":"2016","journal-title":"Acta Radiol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.008_bib0076","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.acra.2021.03.012","article-title":"A systematic review for health disparities and inequities in multiparametric magnetic resonance imaging for prostate cancer diagnosis","volume":"28","author":"El Khoury","year":"2021","journal-title":"Acad Radiol"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0077","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.urology.2018.07.041","article-title":"Association between prostate magnetic resonance imaging and observation for low-risk prostate cancer","volume":"124","author":"Leapman","year":"2019","journal-title":"Urology"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0078","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.adro.2016.07.003","article-title":"Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy","volume":"1","author":"Ajayi","year":"2016","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0079","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.euf.2019.03.016","article-title":"Contemporary trends in magnetic resonance imaging at the time of prostate biopsy: Results from a large private insurance database","volume":"7","author":"Kim","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.008_bib0080","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1007\/s00261-020-02657-6","article-title":"Health disparities and inequities in the utilization of diagnostic imaging for prostate cancer","volume":"45","author":"Washington","year":"2020","journal-title":"Abdom Radiol"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.008_bib0081","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.32388","article-title":"Racial and ethnic disparities in the use of prostate magnetic resonance imaging following an elevated prostate-specific antigen test","volume":"4","author":"Abashidze","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0082","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1002\/cam4.2149","article-title":"Barriers to obtaining prostate multi-parametric magnetic resonance imaging in African-American men on active surveillance for prostate cancer","volume":"8","author":"Walton","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0083","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.urology.2019.02.037","article-title":"Increasing utilization of multiparametric magnetic resonance imaging in prostate cancer active surveillance","volume":"130","author":"Fam","year":"2019","journal-title":"Urology"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0084","doi-asserted-by":"crossref","first-page":"531.e1","DOI":"10.1016\/j.urolonc.2019.03.017","article-title":"A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate","volume":"37","author":"Deebajah","year":"2019","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0085","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jamaoncol.2021.8116","article-title":"Mediators of racial disparity in the use of prostate magnetic resonance imaging among patients with prostate cancer","volume":"8","author":"Leapman","year":"2022","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0086","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2016.07.041","article-title":"Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: A systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique?","volume":"71","author":"Wegelin","year":"2017","journal-title":"Eur Urol"},{"issue":"10071","key":"10.1016\/j.semradonc.2025.04.008_bib0087","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","article-title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study","volume":"389","author":"Ahmed","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0088","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8427","article-title":"Comparison of multiparametric magnetic resonance imaging and targeted biopsy with systematic biopsy alone for the diagnosis of prostate cancer: A systematic review and meta-analysis","volume":"2","author":"Elwenspoek","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0089","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jamasurg.2019.1734","article-title":"Comparison of targeted vs systematic prostate biopsy in men who are biopsy naive: The prospective assessment of image registration in the diagnosis of prostate cancer (PAIREDCAP) study","volume":"154","author":"Elkhoury","year":"2019","journal-title":"JAMA Surg"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0090","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.juro.2018.01.071","article-title":"Evolving use of prebiopsy prostate magnetic resonance imaging in the Medicare population","volume":"200","author":"Rosenkrantz","year":"2018","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0091","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41391-020-0223-5","article-title":"Racial disparity in the utilization of multiparametric MRI\u2013ultrasound fusion biopsy for the detection of prostate cancer","volume":"23","author":"Hoge","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"16_suppl","key":"10.1016\/j.semradonc.2025.04.008_bib0092","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e17007","article-title":"Self-reported race and zip code by men with prostate cancer in New York City and association with access to PSMA PET scans","volume":"40","author":"Nauseef","year":"2022","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0093","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/sj.bjc.6605461","article-title":"Clinical presentation and initial management of Black men and White men with prostate cancer in the United Kingdom: The PROCESS cohort study","volume":"102","author":"Evans","year":"2010","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0094","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/bju.14551","article-title":"Characterising potential bone scan overuse amongst men treated with radical prostatectomy","volume":"124","author":"Kirk","year":"2019","journal-title":"BJU Int"},{"issue":"14","key":"10.1016\/j.semradonc.2025.04.008_bib0095","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.3390\/cancers14143390","article-title":"Racial\/ethnic disparities in mortality related to access to care for major cancers in the United States","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0096","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, part I: Introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0097","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.juro.2016.08.104","article-title":"Racial disparities in active surveillance for prostate cancer","volume":"197","author":"Krishna","year":"2017","journal-title":"J Urol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0098","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.18318","article-title":"Comparison by race of conservative management for low-risk and intermediate-risk prostate cancers in veterans from 2004 to 2018","volume":"3","author":"Parikh","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0099","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/COC.0000000000000547","article-title":"Prevalence, predictors, and implications for appropriate use of active surveillance management among Black men diagnosed with low-risk prostate cancer","volume":"42","author":"Taku","year":"2019","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/pcan.2012.38","article-title":"Race is associated with discontinuation of active surveillance of low-risk prostate cancer: Results from the Duke Prostate Center","volume":"16","author":"Abern","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0101","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1023\/A:1011240019516","article-title":"Socioeconomic status and breast cancer incidence in California for different race\/ethnic groups","volume":"12","author":"Yost","year":"2001","journal-title":"Cancer Causes Cntrl"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0102","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41391-019-0175-9","article-title":"United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015","volume":"23","author":"Butler","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.008_bib0103","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.266","article-title":"The effect of dual eligibility on the quality of active surveillance in patients with newly diagnosed prostate cancer","volume":"42","author":"Faraj","year":"2024","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0104","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.juro.2016.09.115","article-title":"Comparative effectiveness of cancer control and survival after robot-assisted versus open radical prostatectomy","volume":"197","author":"Hu","year":"2017","journal-title":"J Urol"},{"issue":"14","key":"10.1016\/j.semradonc.2025.04.008_bib0105","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2013.53.5096","article-title":"Comparative effectiveness of robot-assisted and open radical prostatectomy in the postdissemination era","volume":"32","author":"Gandaglia","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0106","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.eururo.2011.12.027","article-title":"Perioperative outcomes of robot-assisted radical prostatectomy compared with open radical prostatectomy: Results from the nationwide inpatient sample","volume":"61","author":"Trinh","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0107","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11701-023-01801-w","article-title":"Advancements in robotic surgery: Innovations, challenges and future prospects","volume":"18","author":"Chatterjee","year":"2024","journal-title":"J Robotic Surg"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0108","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.juro.2012.09.033","article-title":"Disparities in access to hospitals with robotic surgery for patients with prostate cancer undergoing radical prostatectomy","volume":"189","author":"Kim","year":"2013","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0109","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-007409","article-title":"Disparities in the receipt of robot-assisted radical prostatectomy: Between-hospital and within-hospital analysis using 2009\u20132011 California inpatient data","volume":"5","author":"Kim","year":"2015","journal-title":"BMJ Open"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0110","doi-asserted-by":"crossref","first-page":"pkae061","DOI":"10.1093\/jncics\/pkae061","article-title":"Racial and ethnic disparities in robot-assisted radical prostatectomy: Testing the physician-level segregated and differential treatment hypotheses","volume":"8","author":"Mao","year":"2024","journal-title":"JNCI Cancer Spectr"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0111","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0112","unstructured":"National Comprehensive Cancer Network. Principles of active surveillance and observation. Accessed January 25, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0113","first-page":"176","article-title":"Impact of androgen deprivation therapy on racial\/ethnic disparities in the survival of older men treated for locoregional prostate cancer","volume":"16","author":"Holmes","year":"2009","journal-title":"Cancer Cntrl"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0114","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40615-018-0508-8","article-title":"Racial, socioeconomic, and geographic disparities in the receipt, timing to initiation, and duration of adjuvant androgen deprivation therapy in men with prostate cancer","volume":"6","author":"Nguyen","year":"2019","journal-title":"J Racial Ethnic Health Disparities"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0115","article-title":"Trends in androgen deprivation use in men with intermediate-risk prostate cancer who underwent radiation therapy","volume":"7","author":"Agrawal","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0116","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.15911","article-title":"Androgen deprivation therapy and outcomes after radiation therapy in Black patients with prostate cancer","volume":"7","author":"Morgan","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0117","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7812\/TPP\/11-096","article-title":"Black men have lower rates than white men of biochemical failure with primary androgen-deprivation therapy","volume":"15","author":"Sassani","year":"2011","journal-title":"Perm J"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0118","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jpainsymman.2009.09.013","article-title":"Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer","volume":"39","author":"Carson","year":"2010","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0119","first-page":"390","article-title":"Social determinants of health mediate racial disparities in cardiovascular disease in men with prostate cancer","volume":"6","author":"Demissei","year":"2024","journal-title":"JACC: CardioOncology"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0120","first-page":"402","article-title":"Disparities in cardio-oncology care among patients with prostate cancer","volume":"6","author":"Dee","year":"2024","journal-title":"JACC: CardioOncology"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0121","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.semradonc.2025.04.008_bib0122","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.semradonc.2025.04.008_bib0123","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.008_bib0124","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.45906","article-title":"Racial and ethnic disparities in use of novel hormonal therapy agents in patients with prostate cancer","volume":"6","author":"Ma","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.008_bib0125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1200\/JCO.18.01279","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with Docetaxel","volume":"37","author":"Halabi","year":"2019","journal-title":"JCO"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0126","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-5347(06)00566-0","article-title":"Clinical outcomes by age in men with hormone refractory prostate cancer: A pooled analysis of 8 cancer and leukemia group B (CALGB) studies","volume":"176","author":"Halabi","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0127","article-title":"Patterns of care of node-positive prostate cancer patients across the United States: A national cancer data base analysis","author":"Moon","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.eururo.2017.07.023","article-title":"Racial disparity in delivering definitive therapy for intermediate\/high-risk localized prostate cancer: The impact of facility features and socioeconomic characteristics","volume":"73","author":"Friedlander","year":"2018","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0129","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.adro.2018.04.013","article-title":"Racial disparities in guideline-concordant cancer care and mortality in the United States","volume":"3","author":"Fang","year":"2018","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.adro.2017.07.002","article-title":"The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States, part 1: African-American patients","volume":"2","author":"McClelland","year":"2017","journal-title":"Adv Radiat Oncol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0131","article-title":"Disparities in the utilization of radiation therapy for prostate cancer in the United States: A comprehensive review","volume":"7","author":"Gardner","year":"2022","journal-title":"Adv Radiat Oncol"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0132","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10196","key":"10.1016\/j.semradonc.2025.04.008_bib0133","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0134","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijrobp.2023.08.027","article-title":"5-Year outcomes from PACE B: an international Phase III randomized controlled trial comparing stereotactic body radiotherapy (SBRT) vs. conventionally fractionated or moderately hypo fractionated external beam radiotherapy for localized prostate cancer","volume":"117","author":"Van As","year":"2023","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0135","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1200\/OP.22.00798","article-title":"Hypofractionation: Contracting or expanding disparities in the receipt of radiation therapy?","volume":"19","author":"Diaz Pardo","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0136","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/OP.22.00383","article-title":"Shorter radiation regimens and treatment noncompletion among patients with breast and prostate cancer in the United States: An analysis of racial disparities in access and quality","volume":"19","author":"Dee","year":"2023","journal-title":"JCO Oncol Pract"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0137","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.ijrobp.2021.10.144","article-title":"Geographic access to radiation therapy facilities in the United States","volume":"112","author":"Maroongroge","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.008_bib0138","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.37165","article-title":"Differential use of radiotherapy fractionation regimens in prostate cancer","volume":"6","author":"Qureshy","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"22","key":"10.1016\/j.semradonc.2025.04.008_bib0139","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.3390\/cancers14225503","article-title":"Pattern of radiotherapy treatment in low-risk, intermediate-risk, and high-risk prostate cancer patients: Analysis of National Cancer Database","volume":"14","author":"Agrawal","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"22","key":"10.1016\/j.semradonc.2025.04.008_bib0140","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.3390\/cancers16223837","article-title":"Health disparities and inequities in the utilization of proton therapy for prostate cancer","volume":"16","author":"Washington","year":"2024","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0141","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.37765\/ajmc.2020.42398","article-title":"A population-based assessment of proton beam therapy utilization in California","volume":"26","author":"Parikh-Patel","year":"2020","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.008_bib0142","article-title":"Association of race with receipt of proton beam therapy for patients with newly diagnosed cancer in the US, 2004-2018","volume":"5","author":"Nogueira","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0143","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14338\/IJPT-21-00002.1","article-title":"Insurance approval for definitive proton therapy for prostate cancer","volume":"8","author":"Mendenhall","year":"2022","journal-title":"Int J Part Ther"},{"issue":"8","key":"10.1016\/j.semradonc.2025.04.008_bib0144","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.jacr.2017.02.040","article-title":"Adoption of radiation technology among privately insured nonelderly patients with cancer in the United States, 2008 to 2014: a claims-based analysis","volume":"14","author":"Pan","year":"2017","journal-title":"J Am Coll Radiol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0145","first-page":"e5703","article-title":"Patient prioritization for Proton Beam therapy in a cost-neutral payer environment: Use of the clinical benefit score for resource allocation","volume":"11","author":"Sharma","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.semradonc.2025.04.008_bib0146","unstructured":"PARTIQoL: Prostate cancer quality of life research. Accessed March 9, 2025.https:\/\/www.massgeneral.org\/cancer-center\/radiation-oncology\/research-and-clinical-trials\/partiqol-clinical-trial#:\u223c:text=PARTIQoL%2C%20or%20Prostate%20Advanced%20Radiation%20Technologies%20Investigating%20Quality,intermediate%20risk%20prostate%20cancer%20across%20the%20United%20States."},{"key":"10.1016\/j.semradonc.2025.04.008_bib0147","unstructured":"A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer (COMPPARE). COMPPARE Powered by Prostate Cancer Patients. Accessed March 9, 2025. https:\/\/comppare.org\/"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.008_bib0148","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.brachy.2021.07.004","article-title":"PSA: declining utilization of prostate brachytherapy","volume":"21","author":"Andring","year":"2022","journal-title":"Brachytherapy"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.008_bib0149","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.brachy.2013.08.005","article-title":"Declining use of brachytherapy for the treatment of prostate cancer","volume":"13","author":"Mahmood","year":"2014","journal-title":"Brachytherapy"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.008_bib0150","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5114\/jcb.2013.37563","article-title":"Racial and socioeconomic disparities in the selection of prostate brachytherapy","volume":"5","author":"Schreiber","year":"2013","journal-title":"J Contemp Brachytherapy"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.008_bib0151","first-page":"1807","article-title":"Expression of the prostate-specific membrane antigen","volume":"54","author":"Israeli","year":"1994","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.008_bib0152","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: A systematic review and network meta-analysis","volume":"48","author":"Alberts","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl 1","key":"10.1016\/j.semradonc.2025.04.008_bib0153","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1007\/s00259-013-2361-7","article-title":"Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET\/CT: Utility and limitations","volume":"40","author":"Jadvar","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"10.1016\/j.semradonc.2025.04.008_bib0154","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/S1470-2045(24)00407-8","article-title":"Radiotherapy and theranostics: A Lancet Oncology Commission","volume":"25","author":"Abdel-Wahab","year":"2024","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.008_bib0155","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1470-2045(24)00041-X","article-title":"Production and regulatory issues for theranostics","volume":"25","author":"Giammarile","year":"2024","journal-title":"Lancet Oncol"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:06:09Z","timestamp":1750791969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":155,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000360"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.008","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Disparities and Inequities in Prostate Cancer Along the Continuum of Care","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}